Brief: Erytech: Positive Results Of Two Clinical Trials Of Eryaspase In Pancreatic Cancer

Phaxiam Therapeutics SA

24/01/2022 06:51

Jan 24 (Reuters) - Erytech Pharma SA  ERYP.PA :
    * ERYTECH ANNOUNCES PRESENTATION OF RESULTS OF TWO CLINICAL
TRIALS
OF ERYASPASE IN PANCREATIC CANCER AT ASCO GI
    * INTERIM RESULTS FROM PHASE 1 RESPECT TRIAL OF ERYASPASE
PLUS
MFOLFIRINOX AS FIRST-LINE TREATMENT FOR ADVANCED PANCREATIC
CANCER PATIENTS, PRESENTED IN A POSTER PRESENTATION, CONFIRM
GOOD SAFETY PROFILE AND DEMONSTRATE ENCOURAGING CLINICAL
ACTIVITY
    * FULL RESULTS FROM TRYBECA-1 PHASE 3 TRIAL OF ERYASPASE IN
SECOND-LINEMETASTATIC PANCREATIC CANCER, PRESENTED AS A
LATE-BREAKING ORAL PRESENTATION, CONFIRM TOP-LINE RESULTS,
REPORTED IN OCTOBER 2021, AND HIGHLIGHT POTENTIAL BENEFIT OF
ERYASPASE IN SUBGROUP OF PATIENTS TREATED WITH FOLFIRI

Source text for Eikon:  ID:nGNEbdC6NH 
Further company coverage:  ERYP.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))